EVOLUS: NEXT BIG THING IN THE PERFORMANCE BEAUTY INDUSTRY
Excited to share an article about Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products. The Company's product Jeuveau has been the fastest-growing neurotoxin in the U.S. for two consecutive years.
Evolus will expand its product portfolio to include a line of five different fillers beginning in 2025. The Company will likely achieve net revenues of $700 million by 2028, representing a 29% CAGR. This rapidly expanding Company serves a highly under-penetrated market and hence seems poised for exponential growth.
Read on to know more: